Comorbidities in Spondyloarthritis.

Area of Science:

• Rheumatology and Immunology
• Internal Medicine
• Public Health

Background:

• Comorbidities significantly increase the burden of spondyloarthritis (SpA), affecting disease activity, disability, and mortality.
• Osteoporosis and cardiovascular disease are highly prevalent in SpA patients, with increased risks compared to the general population.
• Existing gaps in clinical practice highlight the need for improved screening and management of SpA comorbidities.

Purpose of the Study:

• To review the spectrum of comorbidities in spondyloarthritis (SpA).
• To emphasize the importance of screening and managing these comorbidities to improve patient outcomes.
• To identify areas for improvement in the clinical management of SpA.

Main Methods:

• Literature review and synthesis of existing data on comorbidities in spondyloarthritis.
• Analysis of prevalence, risk factors, and management strategies for common comorbidities.
• Evaluation of the gap between clinical recommendations and practice.

Main Results:

• Osteoporosis is the most common comorbidity in SpA, with an elevated fracture risk needing further study.
• Increased cardiovascular risk in SpA is linked to inflammation and traditional risk factors; smoking cessation and risk evaluation are recommended.
• Cancer risk is not inherently increased by SpA itself, but some treatments may pose a risk. Infection risk appears low without TNF-inhibitor use.

Conclusions:

• Addressing comorbidities in SpA is crucial for reducing disease burden and improving patient survival.
• Systematic screening and enhanced management of comorbidities can significantly improve both short- and long-term outcomes for SpA patients.
• Closing the gap between recommended and actual clinical practice for comorbidity management is essential.